Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study

Multiple Sclerosis Journal

Volumn 20, Issue 8, 2014, Pages 1074-1080

  Olberg, Henning K ^a   Cox, Rebecca J ^a,b   Nostbakken, Jane K ^a,b   Aarseth, Jan H ^a,b   Vedeler, Christian A ^a,b   Myhr, Kjell Morten ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Immunity; immunomodulation; immunotherapy; influenza; multiple sclerosis; pandemic influenza; protection; risk; vaccination

Indexed keywords

BETA INTERFERON; GLATIRAMER; INFLUENZA VACCINE; MITOXANTRONE; NATALIZUMAB; IMMUNOLOGIC FACTOR; VACCINE;

2009 H1N1 INFLUENZA; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; SEASONAL INFLUENZA; CASE CONTROL STUDY; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; IMMUNOTHERAPY; INFLUENZA; INFLUENZA A VIRUS (H1N1); MIDDLE AGED; PROCEDURES; RISK FACTOR; SEASON; TIME FACTOR; TREATMENT OUTCOME; VACCINATION; VIROLOGY; ANTIBODY TITER; DRUG RESPONSE; FOLLOW UP; RELAPSE; SWINE INFLUENZA;

ADULT; CASE-CONTROL STUDIES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RISK FACTORS; SEASONS; TIME FACTORS; TREATMENT OUTCOME; VACCINATION; VACCINE POTENCY;

EID: 84904813637     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513513970     Document Type: Article

References (17)

1. Oikonen M, Laaksonen M, Aalto V, et al. Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence. Mult Scler. 2011 ; 17: 672-680
2. Miller AE, Morgante LA, Buchwald LY, et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology. 1997 ; 48: 312-314 (Pubitemid 27087594)
3. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med. 2001 ; 344: 319-326 (Pubitemid 32107639)
4. Auriel E, Gadoth A, Regev K, et al. Seasonal and H1N1v influenza vaccines in MS: Safety and compliance. J Neurol Sci. 2012 ; 314: 102-103
5. Rutschmann OT, McCrory DC, Matchar DB, et al. Immunization and MS: A summary of published evidence and recommendations. Neurology. 2002 ; 59: 1837-1843 (Pubitemid 36076552)
6. Schwid SR, Decker MD, Lopez-Bresnahan M. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology. 2005 ; 65: 1964-1966 (Pubitemid 43970120)
7. Vagberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res. 2012 ; 34: 730-733
8. Mehling M, Hilbert P, Fritz S, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol. 2011 ; 69: 408-413
9. Kappos L, Arroyo R, Izquierdoet G, et al. A controlled study on the effect of fingolimod (FTY720) on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with multiple sclerosis. Mult Scler J. 2011 ; 17: 126
10. Kappos L. Effect of fingolimod on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with MS. ; 2011 Amsterdam, The Netherlands ; 2011..
11. Pathirana RD, Bredholt G, Akselsen PE, et al. A(H1N1)pdm09 vaccination of health care workers: Improved immune responses in low responders following revaccination. J Infect Dis. 2012 ; 206: 1660-1669
12. Pebody RG, Andrews N, Fleming DM, et al. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiol Infect. 2012 ;: 1-11
13. Walker WT, De Whalley P, Andrews N, et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: A multicenter follow-on study. Clin Infect Dis. 2012 ; 54: 661-669
14. Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013 ; 81: 552-558
15. Moriabadi NF, Niewiesk S, Kruse N, et al. Influenza vaccination in MS: Absence of T-cell response against white matter proteins. Neurology. 2001 ; 56: 938-943 (Pubitemid 32290812)
16. McNicholas N, Chataway J. Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J Neurol. 2011 ; 258: 1545-1547
17. De Keyser J, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci. 1998 ; 159: 51-53 (Pubitemid 28365883)